Skip to main content

Table 1 Baseline characteristics of total patients

From: The incidence, risk factors, and clinical outcomes of rhabdomyolysis associated with fenoverine prescription: a retrospective study in South Korea (1999–2014)

Clinical and laboratory parametersTotal patients (n = 22)
Age58.1 ± 9.7
Sex
 Male (%)14 (63.6)
 Female (%)8 (36.4)
Drug duration (days)13.9 ± 8.8
Drug total dose (mg)4072.7 ± 2597.7
WBC (×  103/uL)7.0 ± 3.7
CK (U/L)21,104.0 ± 5.0
LDH (U/L)2430.5 ± 1623.1
AST (U/L)1118.3 ± 635.3
ALT (U/L)383.3 ± 234.5
Albumin (mg/dL)2.8 ± 0.6
BUN (mg/dL)29.8 ± 26.1
Creatinine (mg/dL)1.9 ± 2.1
Sodium (mmol/L)135.6 ± 6.5
Potassium (mmol/L)4.6 ± 0.7
Hospital days21.2 ± 9.7
 Clinical signs and symptoms
 Muscle pain (%)20 (90.9)
 Muscle weakness (%)9 (40.9)
 Oliguria (%)4 (18.2)
 Dark urine (%)3 (13.6)
 DM (%)1 (4.5)
 ARF (%)7 (31.8)
 Death (%)4 (18.2)
Child-Pugh classification
 A (%)3 (15.8)
 B (%)7 (36.8)
 C (%)9 (47.4)
Etiology of LC
 Hepatitis B (%)12 (63.2)
 Hepatitis C (%)2 (10.5)
 Alcohol (%)4 (21.1)
 Cryptogenic (%)1 (5.2)
  1. WBC White Blood Cell, CK Creatine Kinase, LDH Lactate Dehydrogenase, AST Aspartate Transaminase, ALT Alaninine Transminase, BUN Blood Urea Nitrogen, DM Diabetes Mellitus, ARF Acute Renal Failure, LC Liver Cirrhosis